Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* All patients must:~  * Have related donors who are identical at 6 human leukocyte antigens (HLA) loci (A, B and DR) by molecular typing~ * Have a performance status from 0-2~ * Give written informed consent~* Patients with sickle cell disease should have 1 or more of the following:~  * Acute chest syndrome requiring recurrent hospitalization or exchange transfusion~ * Nonhemorrhagic stroke or central nervous system event lasting longer than 24 hours~ * Recurrent vaso-occlusive pain (2 episodes or more per year) or recurrent priapism~ * Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration rate 30-50 percent of normal predicted value)~ * Bilateral proliferative retinopathy and major visual impairment in at least 1 eye~ * Osteonecrosis of multiple joints~* Patients with thalassemia should have 1 or more of the following:~  * Transfusion dependence, defined as a transfusion requirement of greater than or equal to 6 units of packed red blood cells over the past 12 months~ * Iron overload, defined as serum ferritin greater than 500 mcg/L in the absence of infection or biopsy-proven iron overload~ * Presence of 2 or more alloantibodies against red cell antigens~Exclusion criteria:~* Pregnancy~* Acute hepatitis (transaminases greater than 3 times the normal value)~* Cardiac ejection fraction less than 30 percent~* Severe renal impairment (glomerular filtration rate less than 30 percent of predicted normal value)~* Severe residual functional neurologic impairment (other than hemiplegia alone)~* Seropositivity for the human immunodeficiency virus (HIV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Allogeneic stem cell transplantation (Type: EXPERIMENTAL): Participants will receive a nonmyeloablative conditioning regimen of fludarabine and busulfan prior to allogeneic peripheral blood stem cell (CD34+) infusions. FK506 and prednisone will be administered for graft versus host disease (GVHD) prophylaxis.

Based on this trial design, predict the completion outcome and termination type (if applicable).